ARBLI: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Scienture	ARBLI	losartan potassium	SUSPENSION;ORAL	218772	NDA	Scienture LLC	83245-053-06	1 BOTTLE in 1 CARTON (83245-053-06) / 165 mL in 1 BOTTLE	2025-03-19
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 2, 2025

Introduction

Arbli, known generically as Aripiprazole, is a widely prescribed atypical antipsychotic medication used to treat conditions such as schizophrenia, bipolar disorder, and major depressive disorder. Its complex chemical structure and patent protections have traditionally limited manufacturing to a select group of pharmaceutical companies. However, following patent expirations and the entry of generic manufacturers, a dynamic landscape of suppliers now dominates the Aripiprazole supply chain. This article explores the key suppliers, overviewing manufacturing sources, regional distribution, market share, and implications for stakeholders navigating the supply chain.

Overview of Aripiprazole Manufacturing

Aripiprazole's synthesis involves intricate chemical processes requiring specialized facilities compliant with stringent regulatory standards such as Good Manufacturing Practices (GMP). The original innovator, Otsuka Pharmaceutical, developed Aripiprazole, holding key patent rights until patent expiry increasingly permitted generic entries. Generic manufacturers now produce and distribute the drug globally, expanding access while impacting supply chain dynamics.

Major Suppliers of Aripiprazole

1. Original Innovator: Otsuka Pharmaceutical

Otsuka Pharmaceutical, headquartered in Japan, holds the original patent for Aripiprazole. Although patent protections have expired in many jurisdictions, Otsuka retains manufacturing capabilities and markets branded formulations (e.g., Abilify) in select regions. Its involvement is primarily through licensing and strategic partnerships with generic manufacturers.

2. Leading Generic Manufacturers

Post-patent expiry, numerous generic pharmaceutical companies entered the market, significantly increasing the drug's supply volume. Key players include:

Teva Pharmaceutical Industries Ltd.
An Israel-based global leader in generic pharmaceuticals, Teva produces Aripiprazole API (Active Pharmaceutical Ingredient) and finished dosage forms. Their extensive global manufacturing footprint and distribution network make them a primary supplier in North America and Europe [[1]].
Mylan N.V. / Viatris Inc.
Now merged into Viatris, Mylan became one of the earliest generic entrants, offering high-quality Aripiprazole products across multiple markets. Their supply chain includes API manufacturing and finished formulations [[2]].
Sun Pharmaceutical Industries Ltd.
An Indian pharmaceutical behemoth, Sun Pharma manufactures both API and finished dosage forms of Aripiprazole, targeting Asia, Africa, and emerging markets. Their scale and vertical integration boost supply dependability [[3]].
Lupin Limited
Also based in India, Lupin produces Aripiprazole APIs and formulations, serving primarily Asian and African markets with cost-effective production [[4]].
Alkem Laboratories
Focused on Indian and select international markets, Alkem manufactures generic Aripiprazole, emphasizing affordable access [[5]].
Dr. Reddy’s Laboratories
Their manufacturing capabilities in API and finished forms support global distribution, especially in Latin America and Asia [[6]].

3. API Manufacturers outside of India and Israel

Hikma Pharmaceuticals (UK-based)
Engages in manufacturing and distributing generic APIs, including Aripiprazole, primarily serving European and Middle Eastern markets [[7]].
Biocon Limited (India)
Expanding its biosimilar and small molecule portfolio, Biocon produces Aripiprazole API and formulations.

4. Regional and Niche Suppliers

While the aforementioned companies dominate the market, several smaller entities and regional manufacturers contribute to regional supply chains. Their presence is often characterized by limited scale but regional importance, especially in markets with less stringent patent enforcement.

Supply Chain Dynamics and Market Impact

The proliferation of generic manufacturers has resulted in increased global supplies of Aripiprazole, leading to price erosion and greater access. However, supply chain resilience remains critical, especially considering API production concentration in India and China, which supply a significant share of the world's pharmaceuticals.

The evolving regulatory landscape, such as approvals of biosimilar and generic versions, influences supplier dynamics. Quality assurance and patent litigations further impact market entry for new suppliers.

Regional Suppliers and Market Considerations

Region	Key Suppliers	Market Share & Notes
North America	Teva, Mylan/Viatris, Otsuka	Dominated by generics post-patent expiry; branded sales decline.
Europe	Hikma, Teva, Sandoz (Novartis), Otsuka	Strong presence of generic manufacturers; regulatory approvals critical.
Asia-Pacific	Sun Pharma, Lupin, Dr. Reddy’s, Biocon	Largest API production hub; high local market penetration and export.
Middle East/Africa	Hikma, local generics providers	Emerging markets with expanding access to affordable generics.

Implications for Stakeholders

Pharmaceutical Companies: Diversification of suppliers is vital to mitigate risks associated with geopolitical issues, regulatory changes, and API shortages.
Healthcare Providers: Ensuring access to quality-assured generics from reputable suppliers is crucial for patient safety.
Investors: Monitoring market entrants and regional supplier developments offers insights into potential supply stability and pricing trends.
Regulatory Bodies: Promoting stringent quality standards and regulatory harmonization supports a stable supply chain.

Emerging Trends & Future Outlook

API Sourcing Consolidation: Continued reliance on Indian and Chinese API manufacturers necessitates strategic supply chain management.
Regulatory Harmonization: Streamlined approvals can facilitate faster market entry for new suppliers, increasing competition.
Biotech Innovations: Research into biosimilar formulations and alternative delivery mechanisms could affect traditional supply patterns.
Supply Chain Resilience Measures: Diversifying geographically and establishing strategic stockpiles mitigate risks associated with geopolitical conflicts and pandemic-related disruptions.

Key Takeaways

Major suppliers of Aripiprazole include Teva, Mylan/Viatris, Sun Pharma, Lupin, and Otsuka. These companies dominate API production and distribution, especially in North America, Europe, and Asia.
Patent expiries have catalyzed a surge in generic supply, markedly reducing prices and increasing accessibility.
Supply chain resilience hinges on diversification, regional manufacturing, and regulatory cooperation.
India and China remain pivotal in API manufacturing, influencing global supply stability.
Stakeholders should monitor supplier quality certifications, geopolitical developments, and regulatory shifts for informed decision-making.

FAQs

1. Who are the leading manufacturers of Aripiprazole API globally?
Major API manufacturers include Teva, Sun Pharma, Lupin, Dr. Reddy’s, and Hikma, primarily based in India, Israel, and the UK.

2. How has patent expiry affected the supply of Aripiprazole?
Patent expiry facilitated market entry for numerous generic firms, expanding supply, reducing prices, and increasing global accessibility.

3. Are there regional differences in Aripiprazole suppliers?
Yes. India and China dominate API manufacturing; in Europe and North America, regional generic manufacturers provide final formulations.

4. What risks threaten the stability of Aripiprazole supply?
Risks include API shortages due to geopolitical conflicts, regulatory delays, quality issues, and production disruptions.

5. How can stakeholders ensure supply chain reliability for Aripiprazole?
Diversify suppliers, strengthen quality assurance processes, develop regional manufacturing partnerships, and monitor geopolitical/regulatory trends.

Suppliers and packagers for ARBLI

ARBLI

Suppliers for the Pharmaceutical Drug: Arbli